Evidence map›Paper›PMID 26782786›Full record

ArticleOncology reports2016

Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK.

Feng-Ping Pan, Hong-Kun Zhou, He-Qi Bu, Zi-Qiang Chen, Hao Zhang, Lu-Ping Xu, Jian Tang, Qing-Jiang Yu, Yong-Quan Chu, Jie Pan and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Feng-Ping PanDepartment of Surgical Oncology, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Hong-Kun ZhouDepartment of Hepatobiliary Surgery, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
He-Qi BuDepartment of Coloproctological Surgery, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310012, P.R. China.
Zi-Qiang ChenDepartment of Surgical Oncology, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Hao ZhangDepartment of Hepatobiliary Surgery, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Lu-Ping XuDepartment of Hepatobiliary Surgery, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Jian TangDepartment of Surgical Oncology, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Qing-Jiang YuDepartment of Hepatobiliary Surgery, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Yong-Quan ChuDepartment of Surgical Oncology, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Jie PanDepartment of Neurology, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Yong FeiDepartment of Anesthesiology and Pain Medicine, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
Sheng-Zhang LinDepartment of Hepatobiliary-Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China.
Dian-Lei LiuDepartment of Surgery, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, P.R. China.
Liang ChenDepartment of Surgical Oncology, First Hospital of Jiaxing, Jiaxing, Zhejiang 314000, P.R. China.
First Hospital of Jiaxing · CNFirst Affiliated Hospital Zhejiang University · CNHangzhou Hospital of Traditional Chinese Medicine · CNTongde Hospital of Zhejiang Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Aza-2'-deoxycytidine (5-Aza-CdR) is currently acknowledged as a demethylation drug, and causes a certain degree of demethylation in a variety of cancer cells, including pancreatic cancer cells. Emodin, a traditional Chinese medicine (TCM), is an effective monomer extracted from rhubarb and has been reported to exhibit antitumor activity in different manners in pancreatic cancer. In the present study, we examined whether emodin caused demethylation and increased the demethylation of three tumor-suppressor genes P16, RASSF1A and ppENK with a high degree of methylation in pancreatic cancer when combined with 5-Aza-CdR. Our research showed that emodin inhibited the growth of pancreatic cancer Panc-1 cells in a dose- and time-dependent manner. Dot-blot results showed that emodin combined with 5-Aza-CdR significantly suppressed the expression of genome 5mC in PANC-1 cells. In order to verify the effect of methylation, methylation-specific PCR (MSP) and bisulfite genomic sequencing PCR (BSP) combined with TA were selected for the cloning and sequencing. Results of MSP and BSP confirmed that emodin caused faint demethylation, and 5-Aza-CdR had a certain degree of demethylation. When emodin was combined with 5-Aza-CdR, the demethylation was more significant. At the same time, fluorescent quantitative PCR and western blot analysis results confirmed that when emodin was combined with 5-Aza-CdR, the expression levels of P16, RASSF1A and ppENK were increased more significantly compared to either treatment alone. In contrast, the expression levels of DNA methyltransferase 1 (DNMT1) and DNMT3a were more significantly reduced with the combination treatment than the control or either agent alone, further proving that emodin in combination with 5-Aza-CdR enhanced the demethylation effect of 5-Aza-CdR by reducing the expression of methyltransferases. In conclusion, the present study confirmed that emodin in combination with 5-Aza-CdR enhanced the demethylation by 5-Aza-CdR of tumor-suppressor genes p16, RASSF1A and ppENK by reducing the expression of methyltransferases DNMT1 and DNMT3a.

Indexed as

AzacitidineCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p16DecitabineDNA MethylationDrug SynergismEmodinEnkephalinsGene Expression Regulation, NeoplasticHumansNeoplasm ProteinsPancreatic NeoplasmsPromoter Regions, GeneticProtein PrecursorsSequence Analysis, DNAAzacitidineCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DecitabineEmodinEnkephalinsNeoplasm ProteinsproenkephalinProtein PrecursorsRASSF1 protein, humanTumor Suppressor Proteins

Identifiers

PMID26782786
PMCPMC4774670
OpenAlexW2239634118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.